Osphena (Ospemifene) Regulatory Status: US, EU, Canada, and UK

What is ospemifene and how does it work?

Ospemifene is an oral SERM, meaning it activates estrogen receptors in some tissues and blocks them in others. In the vaginal epithelium and bone, it behaves like an estrogen agonist. In breast tissue, it behaves like an estrogen antagonist. This tissue-selective profile is exactly why it became an appealing option for postmenopausal women who cannot or prefer not to use vaginal estrogen.

Genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy, affects up to 84% of postmenopausal women yet remains undertreated, largely because many women are reluctant to use hormone-based therapies or assume nothing non-hormonal exists for them. Ospemifene is neither a hormone nor a lubricant. It is a targeted receptor-level therapy that changes the biology of the vaginal tissue itself.

Mechanism at the receptor level

Ospemifene binds estrogen receptors alpha and beta with moderate affinity. In the vaginal epithelium, receptor activation promotes maturation of superficial cells, reduces pH, and thickens the epithelial lining. These are the same changes that local estrogen produces, but ospemifene achieves them through an oral tablet rather than an intravaginal product. The key phase III RCT by Portman et al. (2013) showed statistically significant improvement in the vaginal maturation index (VMI), significant reduction in vaginal pH, and a meaningful reduction in the most bothersome symptom, dyspareunia, compared with placebo at 12 weeks.

Why the oral route matters for many women

Adherence to intravaginal products is a documented clinical challenge. Some women find applicator-based creams or rings physically uncomfortable, especially when dyspareunia is already severe. Others have dexterity limitations. An oral tablet removes that barrier entirely. The trade-off is systemic exposure, which shapes both the benefit profile (bone-protective signals in early data) and the risk profile (endometrial stimulation, thromboembolic risk), discussed in detail below.

FDA regulatory status (United States)

The FDA granted ospemifene approval on February 26, 2013 under New Drug Application (NDA) 203505. The original approval covered moderate-to-severe dyspareunia as a symptom of vulvovaginal atrophy due to menopause.

Indication broadening in 2018

In 2018, the FDA approved a supplemental NDA that expanded the indication to include moderate-to-severe vaginal dryness as a separate qualifying symptom, distinct from dyspareunia. This was a meaningful regulatory step. A postmenopausal woman whose chief complaint is dryness without pain during intercourse now qualifies for the drug on-label, without needing to meet the dyspareunia threshold.

Boxed warnings the FDA requires

The FDA label carries a boxed warning about two risks. First, endometrial cancer risk: ospemifene has estrogenic effects on the endometrium. The label states that adding a progestogen should be considered in women with a uterus, mirroring the logic applied to systemic estrogen therapy. Second, cardiovascular and stroke risk: the warning is extrapolated from the SERM class (particularly tamoxifen and raloxifene data) rather than from ospemifene-specific outcome trial data, because no large cardiovascular outcomes trial in ospemifene-treated women exists yet. Women and their clinicians should weigh this extrapolated risk, and the absence of direct long-term evidence is an honest limitation.

REMS and post-marketing requirements

Ospemifene does not require a Risk Evaluation and Mitigation Strategy (REMS). The FDA did require post-marketing studies on endometrial safety, and Duchesnay submitted those data through the standard pharmacovigilance pathway.

EU regulatory status (European Union)

The European Medicines Agency (EMA) approved ospemifene under the brand name Senshio in June 2015 for the treatment of moderate-to-severe symptomatic vulvovaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy.

How the EU indication differs from the FDA label

This is a meaningful difference. The EMA restricts Senshio to women who are specifically not suitable for local vaginal estrogen. The FDA label carries no such restriction. In practice, this means a European prescriber must document why intravaginal estrogen is inappropriate before prescribing ospemifene, whereas a US prescriber can offer it as a first-line oral choice without that gatekeeping step.

EMA's assessment of endometrial safety

The EMA's European Public Assessment Report (EPAR) concluded that ospemifene has a mild stimulatory effect on the endometrium and that endometrial hyperplasia rates in clinical trials were low but above placebo. The EMA therefore also recommends progestogen co-administration in women with an intact uterus, consistent with the FDA position.

The table below summarizes how key regulatory bodies have framed the indication differently, which matters practically if you are a Canadian, British, or European woman discussing this drug with your clinician.

| Regulatory body | Brand name | Approval year | Indication framing | Restricts to non-candidates for vaginal estrogen? | |---|---|---|---|---| | FDA (USA) | Osphena | 2013 | Dyspareunia + vaginal dryness due to menopause | No | | EMA (EU) | Senshio | 2015 | Symptomatic VVA in women not suitable for local estrogen | Yes | | Health Canada | Osphena | 2015 | Moderate-to-severe VVA symptoms | Partially (see below) | | MHRA (UK) | Senshio | 2015 (GB procedure post-Brexit) | Symptomatic VVA not suitable for local estrogen | Yes (aligns with EMA) |

Canadian regulatory status

Health Canada approved ospemifene (brand: Osphena) in 2015. The Canadian product monograph, maintained through the Health Canada Drug Product Database, covers moderate-to-severe dyspareunia and vaginal dryness attributable to postmenopausal VVA. The Canadian framing sits between the broad FDA approach and the more restrictive EMA position: local estrogen is mentioned as a preferred first step in prescribing guidance documents, but the product monograph itself does not explicitly restrict use to women who have failed or are ineligible for vaginal estrogen.

Canadian women should know that Osphena is a prescription-only medication in Canada and is not covered under all provincial formularies. Coverage varies by province, and prior authorization is often required even where a formulary listing exists.

UK regulatory status

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) retained the EMA's Senshio marketing authorization via the Great Britain national procedure following Brexit. The product continues to be available in Great Britain under the EMA-aligned indication: symptomatic VVA in postmenopausal women for whom local vaginal estrogen is not appropriate.

In Northern Ireland, which follows EU rules for medicine regulation under the Windsor Framework, the EMA-approved Senshio label applies directly. There is no meaningful clinical difference in the drug itself between territories, but the paperwork governing prescribability differs, and the MHRA maintains its own ongoing pharmacovigilance.

The British Menopause Society has included ospemifene in its guidance on GSM management as an option for women who decline or cannot use local estrogen, aligning with the EMA gatekeeping philosophy.

Ospemifene mechanism: sex-specific pharmacology

Why female physiology specifically matters here

The vaginal epithelium is exquisitely estrogen-sensitive. After menopause, circulating estradiol drops from roughly 100-400 pg/mL in the follicular phase down to below 20 pg/mL, often under 10 pg/mL. This collapse in estrogen drives atrophy: the epithelium thins, glycogen production falls, lactobacilli decline, pH rises above 4.5, and the tissue becomes fragile, inflamed, and prone to microtrauma during intercourse or even routine gynecologic examination.

Ospemifene reverses these changes at the receptor level without delivering estradiol systemically. In the Portman et al. 2013 key trial, women receiving 60 mg ospemifene daily for 12 weeks showed a statistically significant increase in superficial cells on the VMI compared with placebo (p < 0.001) and a significant decrease in vaginal pH. The most bothersome symptom score for dyspareunia improved by 1.34 points on a 0-3 scale versus 0.90 with placebo.

Bone as a secondary female-relevant target

As a SERM, ospemifene also engages estrogen receptors in bone. Early clinical data suggest it may preserve or modestly increase bone mineral density, analogous to the effect seen with raloxifene. However, ospemifene has not been studied or approved as an osteoporosis therapy, and no fracture-endpoint trial exists in ospemifene-treated women. Women with postmenopausal osteoporosis should not rely on ospemifene for skeletal protection in the absence of that evidence.

Breast tissue: the antagonist effect

In breast tissue, ospemifene acts as an estrogen antagonist, similar to tamoxifen. This is pharmacologically reassuring for women with estrogen-receptor-positive breast cancer history, but ospemifene is not FDA-approved for use in women with a history of breast cancer because prospective safety data in that population are absent. Oncology societies and women's-health clinical guidelines consistently recommend that women with hormone-sensitive breast cancer discuss all SERM options, including ospemifene and vaginal estrogen at low doses, with their oncologist.

Pregnancy, lactation, and contraception: what every woman needs to know

Ospemifene is contraindicated in pregnancy. This is not a theoretical warning. As a SERM, ospemifene may cause fetal harm based on animal reproductive toxicity studies. No adequate and well-controlled studies in pregnant humans exist, and the drug should never be used during pregnancy.

Pregnancy category and risk data

The FDA classifies ospemifene under the Pregnancy and Lactation Labeling Rule (PLLR). The prescribing information states that ospemifene caused fetal harm in animal studies and that its use should be discontinued if pregnancy is recognized. Because ospemifene is indicated only for postmenopausal women, the risk of pregnancy on this drug is very low in its intended population. However, perimenopause is not menopause. Women who are perimenopausal, still having any menstrual cycles, or within 12 months of their last period should not assume they are infertile.

Lactation

There are no data on ospemifene transfer into human breast milk. Given its SERM pharmacology, caution is warranted. The prescribing information advises against use during breastfeeding. Because the drug is indicated for postmenopausal women, concurrent lactation would be uncommon, but is not impossible in certain clinical scenarios such as late perimenopause with recent childbirth.

Contraception note for transitional-stage women

A woman who is prescribed ospemifene off-label or who begins it during late perimenopause before confirmed menopause (defined as 12 consecutive months of amenorrhea) should use effective non-hormonal contraception. Combined hormonal contraceptives may interact with ospemifene's SERM receptor competition and are not the preferred contraceptive choice in this scenario. A copper IUD or barrier methods are clinically cleaner options.

Who ospemifene is right for, and who it is not

Life stages and conditions where ospemifene fits

Postmenopausal women with dyspareunia or vaginal dryness. This is the on-label, best-evidenced group. If you are more than 12 months past your last period and are experiencing pain during sex or persistent vaginal dryness that is affecting your quality of life, ospemifene is a reasonable prescription option to discuss.

Postmenopausal women who decline intravaginal products. Women who find vaginal creams, rings, or suppositories unacceptable, or who have physical limitations using them, are good candidates for an oral approach. In the EU and UK, this is the primary gatekeeping criterion.

Women post-breast-cancer treatment (with oncology sign-off). The absence of estrogenic activity in breast tissue makes ospemifene theoretically attractive, but it is not formally approved for this population. The American College of Obstetricians and Gynecologists and oncology societies recommend individualized shared decision-making rather than a blanket prohibition or a blanket green light.

PCOS in the postmenopausal transition. Women with a history of PCOS who reach menopause may have pre-existing endometrial hyperplasia concerns from years of anovulation. Ospemifene's mild endometrial stimulatory effect warrants extra attention in this group, and baseline endometrial assessment before starting is a reasonable clinical step.

Who should not use ospemifene

• Women who are pregnant or may be pregnant.
• Women with undiagnosed abnormal uterine bleeding (must be evaluated first).
• Women with a personal history of venous thromboembolism (VTE): the SERM class carries a VTE risk, and although ospemifene's absolute VTE risk in its phase III trials was not statistically elevated above placebo, the extrapolated class risk is documented.
• Women with active or recent arterial thromboembolic disease (stroke, MI).
• Women on systemic estrogens or other SERMs concurrently: combination use is not studied and not recommended.
• Premenopausal women outside of a clinical trial.

Endometrial safety: a deeper look for women with a uterus

If you have a uterus, endometrial stimulation by ospemifene is the most clinically relevant safety question. In the phase III trials, the rate of endometrial hyperplasia with ospemifene 60 mg was 0.8% at 52 weeks, compared with 0% in the placebo group. Endometrial cancer rates were not statistically significantly different from placebo. The absolute numbers are small, but they are not zero.

Both the FDA and EMA recommend that women with a uterus who use ospemifene long-term discuss progestogen addition with their clinician. In women who also have menopausal hot flushes and are already on combined estrogen-progestogen systemic HRT, adding ospemifene on top is not recommended, because receptor competition and additive endometrial stimulation are both concerns.

Annual endometrial assessment (transvaginal ultrasound or endometrial sampling if uterine bleeding occurs) is a reasonable clinical standard for women using ospemifene beyond 12 months, though no formal screening interval is mandated in current guidelines. The Menopause Society (formerly NAMS) 2023 position statement recommends prompt evaluation of any uterine bleeding in women on ospemifene.

How ospemifene compares to other GSM treatments: a practical frame

The GSM treatment spectrum in postmenopausal women includes non-hormonal options (lubricants, moisturizers, laser therapy), local estrogen (cream, ring, suppository, tablet), ospemifene (oral SERM), intravaginal DHEA (prasterone), and systemic hormone therapy. Each has a different evidence base, route, and risk profile.

Ospemifene occupies a specific niche: it is the only oral non-estrogen, non-androgen prescription therapy for GSM with FDA approval. It suits women who want systemic-level treatment without systemic estrogen and who prefer oral over intravaginal delivery. Prasterone (Intrarosa) is its closest comparator in the GSM space, approved in 2016, but is delivered intravaginally and works through androgen receptor activation rather than estrogen receptor agonism.

No head-to-head RCT between ospemifene and prasterone has been published as of mid-2025. Evidence gaps between these two agents are real, and the comparative effectiveness literature in women with GSM remains thin. This is worth stating plainly: your clinician may have a preference based on clinical experience and your individual history, not on direct comparative trial data.

Frequently asked questions